Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-06-28
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound probes, cloud workflow software, education tools, and embedded ultrasound technology to clinicians, health systems, and development partners.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform upside exists, but proof must catch price
A differentiated handheld ultrasound stack can still widen into software, community care, and embedded licensing. The investment question is no longer whether the product works, but whether those higher-value layers arrive fast enough to justify a stock already priced for meaningful success.

Analysis

Thesis
Butterfly can outgrow typical medtech if its proprietary ultrasound chip becomes the base for a regulated workflow, community-care, and embedded licensing platform, but from today’s valuation the stock needs those higher-value layers to become real revenue engines, not just product extensions.
Last Economy Alignment
AI should lower training and interpretation friction, expanding handheld ultrasound into more settings, and Butterfly owns the regulated chip-plus-workflow stack. The limit is that larger imaging vendors can still bundle over it if Butterfly fails to deepen its software and trust layers.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
The upside depends less on selling more probes and more on improving mix. If Butterfly turns its installed base into enterprise workflow, community-care transaction revenue, and embedded licensing, revenue can compound well above normal device peers. Even then, the stock is already expensive for its current size, so most of the return case comes from execution against a still-compressing multiple, not from a speculative rerating alone.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Butterfly’s device works; it does. The real risk is whether the company can move value capture from probes into workflow, transaction, and licensing layers before incumbents bundle handheld ultrasound more effectively, and before regulatory or supply-chain friction slows its new channels. After the June 2026 rerating, valuation leaves limited room for milestone slippage.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
They control a proprietary ultrasound chip and the regulated software wrapped around it, so cheaper AI can help more people use ultrasound and push more activity onto their stack. The risk is that bigger imaging vendors may still own the buyer relationship unless Butterfly becomes the trusted workflow layer, not just the device.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case